Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29994416 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL2269304 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL2264859 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL31234233 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Hydrochloric Acid SCHEMBL31656540 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Hydrochloric Acid SCHEMBL22031566 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Hydrochloric Acid SCHEMBL1953010 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Hydrochloric Acid SCHEMBL1953011 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| Hydrochloric Acid SCHEMBL28668620 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HTR1ASLC6A2PRKCZ | |
| SCHEMBL3984986 | 0.90 | CHRNB2 (0.55) | CHRNB2CHRNA4HTR1ASLC6A2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240174670-A1 | 4-AMINO-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | US | disclosed |
| CN-115335050-B | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| CN-115335050-A | Compounds and compositions for treating skin conditions | 卡玛瑞制药有限公司 | 2022-11-11 | — | — | CN | disclosed |
| EP-3452465-B1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2020-11-04 | — | — | EP | disclosed |
| EP-3452465-B1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2020-11-04 | — | — | EP | disclosed |
| EP-3534901-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2220068-B1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8309718-B2 | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2220068-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009064835-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | CHRNB2 4323/4885CHRNA4 4248/4885HTR1A 3262/4885 |
| US-20240174670-A1 | 4-AMINO-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 | NLRP3, NLRP1, PYCARD | CHRNB2 3843/4885CHRNA4 3599/4885HTR1A 939/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | CHRNB2 3816/4885CHRNA4 4788/4885HTR1A 3073/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CHRNB2 3816/4885CHRNA4 4788/4885HTR1A 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.